Atlas Trials

Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer

Clinical trial NCT02549677 · COMPLETED

Trial details

NCT number
NCT02549677
Sponsor
Ruijin Hospital
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Breast Neoplasms
Start date
2015-10-01
Primary completion
2020-03-01
Enrollment
294

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.